Modality
Nanobody
MOA
AuroraAi
Target
C5
Pathway
Ferroptosis
Breast Ca
Development Pipeline
Preclinical
~Apr 2013
→ ~Jul 2014
Phase 1
~Oct 2014
→ ~Jan 2016
Phase 2
~Apr 2016
→ ~Jul 2017
Phase 3
Oct 2017
→ Sep 2030
Phase 3Current
NCT03870084
379 pts·Breast Ca
2023-09→TBD·Recruiting
NCT03469144
2,605 pts·Breast Ca
2017-10→2027-09·Recruiting
NCT08685456
2,724 pts·Breast Ca
2021-08→2030-09·Terminated
5,708 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-231.5y awayPh3 Readout· Breast Ca
2030-09-014.4y awayPh3 Readout· Breast Ca
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P3
Recruit…
P3
Termina…
P3
Recruit…
Catalysts
Ph3 Readout
2027-09-23 · 1.5y away
Breast Ca
Ph3 Readout
2030-09-01 · 4.4y away
Breast Ca
RecruitingTerminated|StartCompletionToday
Trials (3)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03870084 | Phase 3 | Breast Ca | Recruiting | 379 | UPCR |
| NCT03469144 | Phase 3 | Breast Ca | Recruiting | 2605 | UPCR |
| NCT08685456 | Phase 3 | Breast Ca | Terminated | 2724 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-9749 | Eli Lilly | Phase 3 | C5 | |
| LLY-1184 | Eli Lilly | NDA/BLA | C5 | |
| RHH-1546 | Roche | Phase 2/3 | C5 | |
| Voxarasimod | Merck & Co | Phase 1/2 | CD19 | |
| TAK-5300 | Takeda | Phase 1 | SMN2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| DSN-791 | Daiichi Sankyo | NDA/BLA | Aβ | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| MRN-5715 | Moderna | NDA/BLA | CDK4/6 | |
| ARG-1250 | Argenx | Phase 2 | C5 |